4 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow FluBlok: new trials by email Literature Review of FluBlok trials Research Report on FluBlok
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults Recombinant Influenza HA Vaccine (H5N1) - Influenza | Phase 2 | Completed | UMN Pharma Inc. | 87 | 2010-10-01 | 2011-02-08 |
| Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults UMN-0501 - Influenza, Virus Diseases | Phase 2 | Completed | UMN Pharma Inc. | 90 | 2009-10-01 | 2010-02-08 |
| Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics Influenza Vaccination - Influenza | Phase 1 / Phase 2 | Completed | Protein Sciences Corporation | 156 | 2006-10-01 | 2009-12-17 |
| Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults Influenza Vaccine, recombinant Hemagglutinin - Influenza | Phase 2 / Phase 3 | Completed | Protein Sciences Corporation | 459 | 2004-11-01 | 2010-01-12 |
Influenza, Human (4) · Influenza in Birds (1) · Virus Diseases (1)
Protein Sciences Corporation (2) · UMN Pharma Inc. (2)
Japan (2) · United States (2)
James C King, MD (1) · John Treanor, MD (1) · Suminobu Ito, MD, PhD (1) · Tetsuo Nakayama, MD, PhD (1)